Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ACTRN12625001422415) titled 'Safety Study to Evaluate Gastrointestinal Adverse Events of Azurity Cabozantinib Tablets vs. CABOMETYX(R) Tablets in Advanced or Metastatic Renal Cell Carcinoma Patients' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Azurity Pharmaceuticals, Inc.
Condition:
Gastrointestinal Discomfort
Metastatic renal cell carcinoma
Gastrointestinal Discomfort
Metastatic renal cell carcinoma
Cancer - Kidney
Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Interven...